Experimental drug targets gut damage in transplant patients

NCT ID NCT05415410

Terminated Disease control Sponsor: VectivBio AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested apraglutide, a drug that helps repair the gut lining, in 31 people with severe gastrointestinal graft-versus-host disease (GVHD) after a stem cell transplant. Participants had GVHD that did not respond to steroids. The study aimed to see if apraglutide is safe and can improve gut symptoms. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apraglutide
What this could lead to: If it works, this could point toward a new treatment option for severe gut complications after stem cell transplant that don't respond to steroids.
What could go wrong: This was a small, early-phase trial that was terminated early, so results are limited. The drug may not improve outcomes and could cause side effects like injection reactions or gallbladder issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GVHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GVHD

Contacts and locations

Locations

Hospital Universitario Virgen del Rocio

Seville, 41013, Spain
Instituto Portugues de Oncologia do Porto Francisco Gentil

Porto, 4200-072, Portugal
Martin Luther Universität Halle-Wittenberg

Halle, 06120, Germany
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
South Austin Medical Center

Austin, Texas, 78704, United States
Stanford Cancer Center

Stanford, California, 94305, United States
The Ohio State University

Columbus, Ohio, 43210, United States
Universitaetsklinikum Duesseldorf

Düsseldorf, 40225, Germany
University of Iowa

Iowa City, Iowa, 52242, United States
Universitätsklinikum Freiburg

Freiburg im Breisgau, 79106, Germany
Universitätsklinikum Hamburg-Eppendorf

Hamburg, 20249, Germany
Universitätsklinikum Köln (AoeR)

Cologne, 50937, Germany
Universitätsmedizin der Johannes Gutenberg - Universität Mainz

Mainz, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.